Life Sciences
Market Access, HTA & Reimbursement Strategy
Zinergy provides senior expertise in Market Access, HTA and reimbursement, with a particular focus on AMNOG and the evolving European HTA environment.
Our work combines strategic advice with the development and delivery of focused HTA and reimbursement work packages, from complex assessment questions to decision-relevant deliverables.
From Evidence to Access
Successful Market Access requires a clear understanding of how evidence will be assessed and translated into reimbursement decisions.
We focus on the points where HTA requirements materially shape strategy, evidence and deliverables – from early scoping and consultation to dossier preparation and independent review.
Who We Support
We work with pharmaceutical and biotechnology companies seeking experienced external expertise for defined Market Access, HTA and reimbursement projects.
Typical assignments arise around key HTA milestones, complex evidence questions and critical strategic decisions.
Market Access Strategy
We address Market Access considerations early and link them to expected HTA and reimbursement requirements.
Our Services Include:
Early HTA and reimbursement considerations
HTA landscape and precedent assessments
Strategic input into evidence and access planning
Identification of key access risks and decision points
AMNOG and EU HTA
We help clients across key HTA milestones in Germany and Europe – from strategic planning and evidence assessment to the preparation and delivery of specific work packages.
Our Services Include:
AMNOG and HTA scoping and strategy
Comparator, endpoint and evidence assessments
Consultations: concept, preparation, training and participation
Dossier modules: concept, authoring and independent review
Strategic support for evolving HTA requirements
Senior Advisory and Project Leadership
We step in where complex Market Access and HTA questions require experienced judgment, focused execution and clear strategic direction.
Our Services Include:
Leadership of defined Market Access and HTA projects and workstreams
Independent review and challenge of strategies, evidence packages and key deliverables
Strategic input at critical decision points
Additional senior capacity during critical project phases
Practice Leadership
Dr. Elke Ziegler
Director, Life Sciences
Market Access, HTA & Reimbursement Strategy
Dr. Elke Ziegler leads Zinergy’s Life Sciences practice and advises pharmaceutical and biotechnology organisations on Market Access, HTA, reimbursement and evidence strategy in Germany and Europe.
She works directly with clients on defined projects and workstreams, providing senior strategic and analytical input on complex Market Access and HTA questions. Her experience spans the pharmaceutical industry, the German healthcare system and consulting, giving her a broad perspective on assessment requirements and decision-making processes. This enables her to assess complex requirements, challenge strategic assumptions and translate evidence and HTA requirements into clear, decision-relevant recommendations.
Discuss Your Market Access Challenge
Whether you are preparing for a HTA milestone, addressing a complex evidence question or looking for experienced senior input on a defined project, we provide focused expertise tailored to your situation.